We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Spice Suppresses Tumor Growth

By Biotechdaily staff writers
Posted on 21 Jul 2005
Curcumin, the yellow component in the spice turmeric and a major ingredient in yellow curry, has been found to suppress melanoma cell growth and trigger tumor cell death, according to new research.

This study also clarifies curcumin's intracellular processes of action in this kind of tumor. More...
The spice also demonstrates anti-inflammatory and antioxidant effects, as well as its anticancer characteristics. In other types of tumors, it has been shown to suppress tumor growth and trigger apoptosis, an intracellular process for cells to commit suicide. To assess the efficacy of curcumin in melanoma, researchers from the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA) treated with melanoma cell lines with curcumin at different doses and for different duration.

The study's findings demonstrated that curcumin treatment decreased cell viability in all three cell lines in a dose-dependent manner. Furthermore, curcumin triggered apoptosis in tumor cells at high concentrations for short periods of time and decreased concentrations for long periods of time--a new finding in the evaluation of curcumin.

Curcumin was found to inhibit two specific proteins normally part of an intracellular pathway that prevents apoptosis when stimulated. Curcumin partially inhibited nuclear factor (NF)-kappa-B and strongly inhibited its upstream stimulator and another independent inhibitor of apoptosis, IKK. However, it did not suppress two other signaling pathways associated with melanomas and tumor proliferation, B-Raf/MEK/ERK and Akt pathways.

"Based on our studies, we conclude the curcumin is a potent suppressor of cell viability and inducer of apoptosis in melanoma cell lines,” reported the authors, adding "Future investigation to determine the effects of curcumin in animal models of melanoma and clinical trials are planned.”

The researchers published their study in the August 15, 2005, issue of the journal Cancer.



Related Links:
M.D. Anderson Cancer Center

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Repetitive Pipette
VWR® Stepper Pro
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.